Applied Clinical Trials-03-01-2024

Industry leaders discuss how technology can help companies adapt to the regulatory changes and accomplish their DE&I goals.

What are the necessary next steps—for all parties involved—in improving diversity in clinical trials?

Exploring a human-centered, holistic approach for equitable trial outcomes.

Truly moving the needle in clinical trial diversity comes down to embracing two fundamental pieces of the DE&I puzzle.

Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.

Exploring ways to boost the adoption of eCOA provider-specific libraries—an often-frustrating migration process, but one with significant payoffs in simplified workflows and reduced timelines.

Analysis assesses the relative percentage of quality issues detected via SDM that clinical study teams considered critical.

Spotlight on poor compliance, access, and usefulness of trial results summaries.

Leveraging an essential, new set of behaviorally informed best practices to break free from the constraints of the Iron Triangle of Clinical Trial Complexity.

The six steps to designing a successful diversity action plan for a clinical trial protocol.

Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.